VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice

• DOI: 10.3748/wjg.v24.i37.4254
• Publication Date: 2018-09-29T04:02:07Z
• Authors: Chun-Sai-Er Wang; Wen-Bin Li; Hong-Ying Wang; Yi-Ming Ma; Xin-Hua Zhao; Hong Yang; Jia-Ming Qian; Jing-Nan Li
• Keywords: Bifidobacterium breve; Intestinal mucosa

To investigate the effects of VSL#3 on tumor formation, and fecal intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model.C57BL/6 were administered AOM/DSS to develop ulcerative colitis (UC) carcinogenesis model. Mice treated with 5-ASA (75 mg/kg/d), (1.5 × 109 CFU/d), or combined by gavage from day AOM injection for three months (five days/week). The load was compared each group, necrosis factor (TNF-α) interleukin (IL)-6 levels evaluated colon tissue. stool mucosa samples collected analyze differences 16s rDNA sequencing method.VSL#3 significantly reduced AOM/DSS-induced model decreased level TNF-α IL-6 group had a lower Lactobacillus higher Oscillibacter Lachnoclostridium than control group. After intervention VSL#3, Bacillus Lactococcus increased, while reduced. increased Oscillibacter. analysis showed Bifidobacterium Ruminococcaceae_UCG-014 Alloprevotella as supplementation increased. both Bifidobacterium.VSL#3 can prevent UC-associated mice, reduce colonic inflammation levels, rebalance microbiota.